AU2022425608A1 - Methods for attenuating atopic march by administering an il-4/il-13 antagonist - Google Patents

Methods for attenuating atopic march by administering an il-4/il-13 antagonist Download PDF

Info

Publication number
AU2022425608A1
AU2022425608A1 AU2022425608A AU2022425608A AU2022425608A1 AU 2022425608 A1 AU2022425608 A1 AU 2022425608A1 AU 2022425608 A AU2022425608 A AU 2022425608A AU 2022425608 A AU2022425608 A AU 2022425608A AU 2022425608 A1 AU2022425608 A1 AU 2022425608A1
Authority
AU
Australia
Prior art keywords
subject
seq
antagonist
years old
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022425608A
Other languages
English (en)
Inventor
Gregory GEBA
Dateng Li
Judy Xiang Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2022425608A1 publication Critical patent/AU2022425608A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022425608A 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist Pending AU2022425608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295113P 2021-12-30 2021-12-30
US63/295,113 2021-12-30
PCT/US2022/082535 WO2023130010A1 (en) 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Publications (1)

Publication Number Publication Date
AU2022425608A1 true AU2022425608A1 (en) 2024-08-15

Family

ID=85199428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022425608A Pending AU2022425608A1 (en) 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Country Status (10)

Country Link
US (1) US20230220089A1 (https=)
EP (1) EP4457245A1 (https=)
JP (1) JP2025501239A (https=)
KR (1) KR20240135618A (https=)
CN (1) CN118355034A (https=)
AU (1) AU2022425608A1 (https=)
CA (1) CA3241374A1 (https=)
IL (1) IL313897A (https=)
MX (1) MX2024006053A (https=)
WO (1) WO2023130010A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
CA2646626A1 (en) 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012049278A1 (en) 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
JP2016522168A (ja) 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111686247B (zh) 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
MX2022011730A (es) * 2020-03-27 2022-10-13 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
US20230374144A1 (en) 2020-09-10 2023-11-23 Staidson (Beijing) Biopharmaceutical Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof
KR20230123981A (ko) 2020-12-23 2023-08-24 누맙 세러퓨틱스 아게 Il-4r에 결합하는 항체 가변 도메인
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31

Also Published As

Publication number Publication date
IL313897A (en) 2024-08-01
CA3241374A1 (en) 2023-07-06
EP4457245A1 (en) 2024-11-06
WO2023130010A1 (en) 2023-07-06
US20230220089A1 (en) 2023-07-13
JP2025501239A (ja) 2025-01-17
CN118355034A (zh) 2024-07-16
WO2023130010A8 (en) 2023-08-10
MX2024006053A (es) 2024-07-29
KR20240135618A (ko) 2024-09-11

Similar Documents

Publication Publication Date Title
US20240199751A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
US20240350625A1 (en) Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergy
KR102462039B1 (ko) Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
AU2019204577A1 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
AU2021244266A1 (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
US20230220089A1 (en) Methods for attenuating atopic march by administering an il-4/il-13 antagonist
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r
AU2017321682B2 (en) Methods for preventing or treating allergy by administering an IL-4R antagonist
AU2023384154A1 (en) Methods for improving bone growth by administering an il-4r antagonist
IL271284B (en) Methods of treating or preventing asthma by administering an antagonist to -il-r4